The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9770498 B1

PDF
Full Text
Expired
Date of Patent:
Sep. 26, 2017

Filed:

May. 22, 2014
Applicant:

Oncotherapy Science, Inc., Kanagawa, JP;

Inventors:

Yasuharu Nishimura, Kumamoto, JP;

Yusuke Tomita, Kumamoto, JP;

Masatoshi Hirayama, Kumamoto, JP;

Ryuji Osawa, Kawasaki, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 31/7088 (2006.01); C07K 14/65 (2006.01); A61K 35/17 (2015.01); A61K 35/26 (2015.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 31/7088 (2013.01); A61K 35/17 (2013.01); C07K 14/65 (2013.01); A61K 35/26 (2013.01); A61K 38/00 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/57 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01);
Abstract

Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. The peptides of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors expressing IMP-3.


Find Patent Forward Citations

Loading…